The implementation of the IRA is currently subject to ongoing litigation that challenges the constitutionality of the IRA’s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.
All entries for: Endocrinology
February 27, 2026
VYNE Therapeutics Inc
Neutral Outlook
Stewartsville, NJ
1-50 employees
For example, on August 16, 2022, the Inflation Reduction Act of 2022 (“IRA”) was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025.
Disease Area: Endocrinology, Immune Diseases, Rare Diseases
Drug Type: Biologic
February 27, 2026
Amneal Pharmaceuticals Inc
Negative Outlook
Bridgewater, NJ
5,001-10,000 employees
The drug pricing reforms in the IRA have impacted, and may impact in the future, the prices of certain of our products.
Disease Area: Cardiology, Dermatology, Endocrinology, Hematology, Infectious Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
February 26, 2026
Opko Health Inc
Neutral Outlook
Waltham, MA
501-1,000 employees
The IRA has had and will likely continue to have a significant impact on the pharmaceutical industry.
Disease Area: Endocrinology, Immune Diseases, Infectious Diseases, Oncology
Drug Type: Biologic, Small Molecule
February 26, 2026
Crinetics Pharmaceuticals Inc.
Neutral Outlook
San Diego, CA
501-1,000 employees
While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.
Disease Area: Endocrinology, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
February 26, 2026
Rhythm Pharmaceuticals
Neutral Outlook
Boston, MA
201-500 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Endocrinology, Metabolic Diseases, Multiple, Rare Diseases
Drug Type: Small Molecule
February 24, 2026
Beta Bionics Inc
Irvine, CA
201-500 employees
For example, on August 16, 2022, the Inflation Reduction Act of 2022 (IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025.
Disease Area: Endocrinology
Drug Type: Medical Device
February 24, 2026
Corcept Therapeutics, Inc.
Neutral Outlook
Redwood City, CA
501-1,000 employees
The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at the HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business.
Disease Area: Endocrinology, Oncology
Drug Type: Small Molecule
February 24, 2026
AbCellera Biologics
Negative Outlook
British Columbia
501-1,000 employees
The implementation of cost-containment measures or other healthcare reforms may prevent us from generating revenue, achieving profitability, or commercializing our drug candidates if approved.
Disease Area: Dermatology, Endocrinology, Immune Diseases, Oncology
Drug Type: Biologic